Generic placeholder image

Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents

Editor-in-Chief

ISSN (Print): 1568-0142
ISSN (Online): 1875-6131

Update on the Therapy of Behçets Disease

Author(s): T. Arayssi and A. Hamdan

Volume 4, Issue 3, 2005

Page: [339 - 348] Pages: 10

DOI: 10.2174/1568014054065230

Price: $65

Abstract

Behçets disease is a chronic inflammatory systemic disorder, characterized by a relapsing and remitting course. The main histopathological finding is a widespread vasculitis of the arteries and veins of any size. The prevalence of BD is highest in the Middle East, Mediterranean region and Asia. The usual age of onset is around 30, and the male to female ratio varies with the ethnic background. The cause of BD remains unknown. It is presumed to be multifactorial involving infectious triggers, genetic predisposition, and dysregulation of the immune system. The main objectives of therapy of BD are to relieve its symptoms, decrease recurrences and prevent irreversible damage. This choice, however, is limited by the paucity of high quality therapy trials. Therapy studies for this disease in general, lack high methodological quality and common outcome measures, making treatment of this disease for the most part empirical. Most randomized studies have focused on the treatment of ocular, mucocutaneous and musculoskeletal diseases, while data on the treatment of the other manifestations is based on uncontrolled data.

Keywords: behcets disease, therapy, randomized clinical trials, diagnosis, pathogenesis, clinical manifestations

« Previous

Rights & Permissions Print Export Cite as
© 2024 Bentham Science Publishers | Privacy Policy